Gojnic, Miroslava (9434266300)Miroslava (9434266300)GojnicFazlagic, A. (23496293200)A. (23496293200)FazlagicLikic, I. (23497909500)I. (23497909500)LikicStefanovic, A. (8613866900)A. (8613866900)StefanovicVidakovic, S. (9434348100)S. (9434348100)VidakovicPervulov, M. (6602872337)M. (6602872337)PervulovPetkovic, S. (7005164142)S. (7005164142)PetkovicMostic, T. (6506343126)T. (6506343126)MosticMiljic, P. (6604038486)P. (6604038486)MiljicBogdanovic, A. (6603686934)A. (6603686934)Bogdanovic2025-06-132025-06-132005https://doi.org/10.1007/s00404-005-0739-xhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-39049184899&doi=10.1007%2fs00404-005-0739-x&partnerID=40&md5=01f95f82c9182116dc637bd5b46d30e6https://remedy.med.bg.ac.rs/handle/123456789/11034AIM: The aim of the study was to analyze the effectiveness of the application of DDAVP (desmopressin) and Hemate P with cryoprecipitate pre- and postpartum in patients with von Willebrand disease. METHODS: We monitored 32 patients with von Willebrand disease during the study period 1993-2003. DDAVP was applied in the 36th/37th week of gestation and cryoprecipitate and fresh frozen plasma were applied 1 day before and 3 days after delivery. DDAVP treatment continued for 4 weeks. Factor VIII (Hemate P) at the day of delivery RESULTS: No complications occurred in the studied population. CONCLUSION: Precipitation of DDAVP, Hemate P, and cryoprecipitate may help in the treatment of pregnant women with von Willebrand disease.